{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:17:06Z","timestamp":1781763426549,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1007\/s10637-019-00742-2","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T06:07:06Z","timestamp":1550729226000},"page":"791-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1\u2013ALK fusion: a case report"],"prefix":"10.1007","volume":"37","author":[{"given":"Kazunori","family":"Honda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"742_CR1","first-page":"91","volume-title":"Inflammatory myofibroblastic tumour","author":"CD Fletcher","year":"2013","unstructured":"Fletcher CD, Mertens F, Bridge JA (2013) Inflammatory myofibroblastic tumour. WHO Press, Geneva, pp 91\u201393"},{"key":"742_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/00000478-199508000-00001","volume":"19","author":"CM Coffin","year":"1995","unstructured":"Coffin CM, Watterson J, Priest JR, Dehner LP (1995) Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 19:859\u2013872","journal-title":"Am J Surg Pathol"},{"key":"742_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3904\/kjim.2002.17.4.252","volume":"17","author":"JH Kim","year":"2002","unstructured":"Kim JH, Cho JH, Park MS, Chung JH, Lee JG, Kim YS, Kim SK, Kim SK, Shin DH, Choi BW, Choe KO, Chang J (2002) Pulmonary inflammatory pseudotumor--a report of 28 cases. Korean J Intern Med 17:252\u2013258","journal-title":"Korean J Intern Med"},{"key":"742_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1378\/chest.105.5.1574","volume":"105","author":"T Bando","year":"1994","unstructured":"Bando T, Fujimura M, Noda Y, Hirose J, Ohta G, Matsuda T (1994) Pulmonary plasma cell granuloma improves with corticosteroid therapy. Chest 105:1574\u20131575","journal-title":"Chest"},{"key":"742_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jso.20516","volume":"94","author":"SJ Kovach","year":"2006","unstructured":"Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, Koniaris LG (2006) Inflammatory myofibroblastic tumors. J Surg Oncol 94:385\u2013391","journal-title":"J Surg Oncol"},{"key":"742_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/modpathol.3880352","volume":"14","author":"CM Coffin","year":"2001","unstructured":"Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA (2001) Alk1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 14:569\u2013576","journal-title":"Mod Pathol"},{"key":"742_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2159-8290.CD-12-0009","volume":"2","author":"H Mano","year":"2012","unstructured":"Mano H (2012) ALKoma: a cancer subtype with a shared target. Cancer Discov 2:495\u2013502","journal-title":"Cancer Discov"},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","volume":"4","author":"CM Lovly","year":"2014","unstructured":"Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM (2014) Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4:889\u2013895","journal-title":"Cancer Discov"},{"key":"742_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","volume":"157","author":"B Lawrence","year":"2000","unstructured":"Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157:377\u2013384","journal-title":"Am J Pathol"},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","volume":"363","author":"JE Butrynski","year":"2010","unstructured":"Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Janne PA, Maki RG, Demetri GD, Shapiro GI (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363:1727\u20131733","journal-title":"N Engl J Med"},{"key":"742_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children's oncology group phase 1 consortium study. Lancet Oncol 14:472\u2013480","journal-title":"Lancet Oncol"},{"key":"742_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","volume":"19","author":"H Sakamoto","year":"2011","unstructured":"Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679\u2013690","journal-title":"Cancer Cell"},{"key":"742_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.12659\/AJCR.903698","volume":"18","author":"C Yuan","year":"2017","unstructured":"Yuan C, Ma MJ, Parker JV, Mekhail TM (2017) Metastatic anaplastic lymphoma kinase-1 (ALK-1)-rearranged inflammatory myofibroblastic sarcoma to the brain with leptomeningeal involvement: favorable response to serial ALK inhibitors: a case report. Am J Case Rep 18:799\u2013804","journal-title":"Am J Case Rep"},{"key":"742_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/jjco\/hyx133","volume":"47","author":"M Saiki","year":"2017","unstructured":"Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M (2017) Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Jpn J Clin Oncol 47:1189\u20131192","journal-title":"Jpn J Clin Oncol"},{"key":"742_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.oraloncology.2011.09.004","volume":"48","author":"HS Ong","year":"2012","unstructured":"Ong HS, Ji T, Zhang CP, Li J, Wang LZ, Li RR, Sun J, Ma CY (2012) Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features. Oral Oncol 48:141\u2013148","journal-title":"Oral Oncol"},{"key":"742_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1440-1827.2006.02012.x","volume":"56","author":"H Yamamoto","year":"2006","unstructured":"Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M (2006) Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene. Pathol Int 56:584\u2013590","journal-title":"Pathol Int"},{"key":"742_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/00000478-200105000-00009","volume":"25","author":"JJ G\u00f3mez-Rom\u00e1n","year":"2001","unstructured":"G\u00f3mez-Rom\u00e1n JJ, S\u00e1nchez-Velasco P, Ocejo-Vinyals G, Hern\u00e1ndez-Nieto E, Leyva-Cobi\u00e1n F, Val-Bernal JF (2001) Human herpesvirus-8 genes are expressed in pulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). Am J Surg Pathol 25:624\u2013629","journal-title":"Am J Surg Pathol"},{"key":"742_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/modpathol.2017.191","volume":"31","author":"BC Dickson","year":"2018","unstructured":"Dickson BC, Swanson D, Charames GS, Fletcher CD, Hornick JL (2018) Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases. Mod Pathol 31:753\u2013762","journal-title":"Mod Pathol"},{"key":"742_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/PAS.0b013e318287791f","volume":"37","author":"ES d'Amore","year":"2018","unstructured":"d'Amore ES, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E (2018) STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol 37:780\u2013786","journal-title":"Am J Surg Pathol"},{"key":"742_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3324\/haematol.2010.033514","volume":"96","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hatano S, Asaka R, Noguchi M, Mano H (2011) Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 96:464\u2013467","journal-title":"Haematologica"},{"key":"742_CR21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) Investigators P: first-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167\u20132177","journal-title":"N Engl J Med"},{"key":"742_CR22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jtho.2017.06.070","volume":"12","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT (2017) Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol 12:1552\u20131560","journal-title":"J Thorac Oncol"},{"key":"742_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29\u201339","journal-title":"Lancet"},{"key":"742_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, Investigators AT (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829\u2013838","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00742-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:34:41Z","timestamp":1678559681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00742-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00742-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"4 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for the publication of this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}